Natural killer cells and hepatitis C: Action and reaction

Gut

Volumn 60, Issue 2, 2011, Pages 268-278

  Cheent, Kuldeep ^a   Khakoo, Salim I ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEATH RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

CELL KILLING; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; STELLATE CELL; TH1 CELL; TH2 CELL; VIRAL CLEARANCE; VIRUS VIRULENCE;

ACUTE DISEASE; ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LIVER; LIVER TRANSPLANTATION; RECEPTORS, NATURAL KILLER CELL;

EID: 78651083396     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.212555     Document Type: Review

References (106)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
4. Corado J, Toro F, Rivera H, et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997;109:451-7.
5. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
6. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
7. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007;179:89-94.
8. Korbel DS, Norman PJ, Newman KC, et al. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals. J Immunol 2009;182:6426-34.
9. Stegmann KA, Bjorkstrom NK, Liermann H, et al. Interferon-alfa-induced tumor necrosis factor-related apoptosis-inducing ligand on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010;138:1885-97.
10. Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology 2009;126:449-57.
11. Wisse E, van't Noordende JM, van der Meulen J, et al. The pit cell: description of a new type of cell occurring in rat liver sinusoids and peripheral blood. Cell Tissue Res 1976;173:423-35.
12. Bouwens L, Remels L, Baekeland M, et al. Large granular lymphocytes or "pit cells" from rat liver: isolation, ultrastructural characterization and natural killer activity. Eur J Immunol 1987;17:37-42.
13. Kiessling R, Klein E, Pross H, et al. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975;5:117-21.
14. Kaneda K, Wake K. Distribution and morphological characteristics of the pit cells in the liver of the rat. Cell Tissue Res 1983;233:485-505. (Pubitemid 14226904)
15. Vanderkerken K, Bouwens L, De NW, et al. Origin and differentiation of hepatic natural killer cells (pit cells). Hepatology 1993;18:919-25.
16. Lassen MG, Lukens JR, Dolina JS, et al. Intrahepatic IL-10 maintains NKG2A+Ly49- liver NK cells in a functionally hyporesponsive state. J Immunol 2010;184:2693-701.
17. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-300.
18. Melhem A, Muhanna N, Bishara A, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006;45:60-71. (Pubitemid 43850614)
19. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009;130:16-26.
20. Baroni GS, D'Ambrosio L, Curto P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189-99.
21. Morishima C, Paschal DM, Wang CC, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006;43:573-80.
22. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-4.
23. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006;214:186-201.
24. Romero V, Azocar J, Zuniga J, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in hepatitis C virus infection outcome. Mol Immunol 2008;45:2429-36.
25. Fadda L, Borhis G, Ahmed P, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A 2010;107:10160-5.
26. Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008;180:3969-79.
27. Ahlenstiel G, Martin MP, Gao X, et al. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017-26.
28. Schulte D, Vogel M, Langhans B, et al. The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. J Infect Dis 2009;200:1397-401.
29. Strong RK, Holmes MA, Li P, et al. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003;278:5082-90.
30. An P, Thio CL, Kirk GD, et al. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 2008;198:1159-65.
31. Hennig BJ, Frodsham AJ, Hellier S, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007;27:1134-43.
32. Houldsworth A, Metzner M, Rossol S, et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 2005;25:271-6.
33. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A 2007;104:985-90.
34. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003;55:362-9. (Pubitemid 37255487)
35. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45, 1345.
36. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
37. Amadei B, Urbani S, Cazaly A, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010;138:1536-45.
38. Pelletier S, Drouin C, Bedard N, et al. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol 2010;53:805-16.
39. Fisicaro P, Valdatta C, Boni C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009;58:974-82.
40. Das A, Maini MK. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 2010;28:126-32.
41. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009;51:458-67.
42. Dessouki O, Kamiya Y, Nagahama H, et al. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. Biochem Biophys Res Commun 2010;393:331-7.
43. Meier UC, Owen RE, Taylor E, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005;79:12365-74.
44. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-60, 1160.
45. Appasamy R, Bryant J, Hassanein T, et al. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. Clin Immunol Immunopathol 1994;73:350-7.
46. Bonavita MS, Franco A, Paroli M, et al. Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tissue React 1993;15:11-16.
47. Golden-Mason L, Madrigal-Estebas L, McGrath E, et al. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 2008;57:1121-8.
48. Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 2003;171:5423-9.
49. DeMaria A, Fogli M, Mazza S, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007;37:445-55.
50. Lin AW, Gonzalez SA, Cunningham-Rundles S, et al. CD56 (+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 2004;137:408-16.
51. Lee S, Watson MW, Flexman JP, et al. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy. J Med Virol 2010;82:568-74.
52. Gonzalez VD, Falconer K, Bjorkstrom NK, et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009;183:6612-18.
53. Mavilio D, Lombardo G, Kinter A, et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006;203:2339-50.
54. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-74. (Pubitemid 35403989)
55. Jinushi M, Takehara T, Tatsumi T, et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004;173:6072-81.
56. Nattermann J, Nischalke HD, Hofmeister V, et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005;166:443-53.
57. Nattermann J, Feldmann G, Ahlenstiel G, et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006;55:869-77.
58. Takehara T, Hayashi N. Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity. Clin Gastroenterol Hepatol 2005;3:S78-81.
59. Harrison RJ, Ettorre A, Little AM. Association of NKG2A with treatment for chronic Hepatitis C Virus Infection. Clin Exp Immunol 2010;161:306-14.
60. Ahlenstiel G, Titerence RH, Koh C, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa- dependent manner. Gastroenterology 2010;138:325-35.
61. Bryceson YT, Fauriat C, Nunes JM, et al. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol 2010;612:335-52.
62. Yawata M, Yawata N, Draghi M, et al. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008;112:2369-80.
63. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002;195:35-41.
64. Par G, Rukavina D, Podack ER, et al. Decrease in CD3-negative- CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J Hepatol 2002;37:514-22.
65. Duesberg U, Schneiders AM, Flieger D, et al. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 2001;35:650-7.
66. Yoon JC, Shiina M, Ahlenstiel G, et al. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 2009;49:12-21.
67. Ochi M, Ohdan H, Mitsuta H, et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004;39:1321-31. (Pubitemid 38569054)
68. Jo J, Aichele U, Kersting N, et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 2009;136:1391-401.
69. Crotta S, Brazzoli M, Piccioli D, et al. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010;52:183-90.
70. Wang SH, Huang CX, Ye L, et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat 2008;15:855-64.
71. Polyak SJ, Khabar KS, Rezeiq M, et al. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001;75:6209-11.
72. Peritt D, Robertson S, Gri G, et al. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998;161: 5821-4.
73. Abel M, Sene D, Pol S, et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006;44:1607-16.
74. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004;113:963-72.
75. Knapp S, Warshow U, Hegazy D, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010;51:1168-75.
76. Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010;84:475-81.
77. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009;23:1625-37.
78. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-80.
79. Yamagiwa S, Matsuda Y, Ichida T, et al. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res 2008;38:664-72.
80. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45.
81. Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003;77:8299-309.
82. Cerny A, McHutchison JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995;95:521-30.
83. Konan KV, Giddings TH Jr, Ikeda M, et al. Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J Virol 2003;77:7843-55.
84. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-9.
85. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009;86:513-28.
86. Radaeva S, Sun R, Jaruga B, et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130:435-52.
87. Kawarabayashi N, Seki S, Hatsuse K, et al. Decrease of CD56 (+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000;32:962-9.
88. Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008;129:428-37.
89. Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 1990;65:926-30.
90. Ghiringhelli F, Menard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005;202:1075-85.
91. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J, et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2005;192:162-5.
92. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
93. Ashiru O, Boutet P, Fernandez-Messina L, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010;70:481-9.
94. Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003;171:6891-9.
95. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
96. Kohga K, Takehara T, Tatsumi T, et al. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010;51:1264-73.
97. Bishara A, Brautbar C, Zamir G, et al. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005;66:1099-105.
98. Hanvesakul R, Spencer N, Cook M, et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant 2008;8:1931-41.
99. Parham P. Immunology. NK cells lose their inhibition. Science 2004;305:786-7.
100. Tran TH, Middleton D, Dohler B, et al. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival. Am J Transplant 2009;9:1674-8.
101. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
102. de Arias AE, Haworth SE, Belli LS, et al. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009;15:390-9.
103. Varchetta S, Oliviero B, Francesca DM, et al. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. J Hepatol 2009;50:314-22.
104. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341-55.
105. Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006;43:362-72.
106. Ohira M, Ohdan H, Mitsuta H, et al. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006;82:1712-19.